140 related articles for article (PubMed ID: 16583564)
1. [Platinum complexes in cancer pharmacy. Individual patient cytostatic preparation].
Warnke U
Pharm Unserer Zeit; 2006; 35(2):110-6. PubMed ID: 16583564
[No Abstract] [Full Text] [Related]
2. [Iproplatin--advantages and disadvantages of a new platinum cytostatic agent].
Hejl J; Hejlová N
Cas Lek Cesk; 1988 Apr; 127(15):467-70. PubMed ID: 3378253
[No Abstract] [Full Text] [Related]
3. CL 287,110 and CL 286,558.
Cancer Invest; 1989; 7(5):537. PubMed ID: 2620257
[No Abstract] [Full Text] [Related]
4. Satraplatin. BMS 182751, BMY 45594, JM 216.
Drugs R D; 2002; 3(1):67-71. PubMed ID: 11881537
[No Abstract] [Full Text] [Related]
5. Which patients with early-stage triple-negative breast cancer should receive a platinum?
Sikov WM
Clin Adv Hematol Oncol; 2017 Jul; 15(7):510-514. PubMed ID: 28749912
[No Abstract] [Full Text] [Related]
6. Platinum hypersensitivity and desensitization.
Miyamoto S; Okada R; Ando K
Jpn J Clin Oncol; 2015 Sep; 45(9):795-804. PubMed ID: 26056327
[TBL] [Abstract][Full Text] [Related]
7. [Cisplatin (platidiam) and the prospects for using complex platinum compounds in the clinical chemotherapy of malignant tumors].
Gorbunova VA
Vopr Onkol; 1989; 35(3):325-30. PubMed ID: 2705315
[TBL] [Abstract][Full Text] [Related]
8. [Cytostatic platinum complexes: an unexpected discovery with considerable consequences].
Köpf-Maier P; Köpf H
Naturwissenschaften; 1986 May; 73(5):239-47. PubMed ID: 3736675
[TBL] [Abstract][Full Text] [Related]
9. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.
Mathé G; Kidani Y; Segiguchi M; Eriguchi M; Fredj G; Peytavin G; Misset JL; Brienza S; de Vassals F; Chenu E
Biomed Pharmacother; 1989; 43(4):237-50. PubMed ID: 2675999
[TBL] [Abstract][Full Text] [Related]
10. [Platinum drugs].
Kusaba H; Baba E
Nihon Rinsho; 2015 Feb; 73 Suppl 2():143-5. PubMed ID: 25831739
[No Abstract] [Full Text] [Related]
11. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of patients with intestinal cancer. Increased neurotoxicity after oxaliplatin and related liver metastasis].
Junker A; Kretzschmar A; Böhm U; Tannapfel A; Langenbahn D; Pieck AC; Jaehde U
Med Monatsschr Pharm; 2004 Oct; 27(10):349-52. PubMed ID: 15527179
[No Abstract] [Full Text] [Related]
13. Platinum compounds.
Belani CP; Van Echo DA; Aisner J
Curr Opin Oncol; 1989 Dec; 1(2):186-91. PubMed ID: 2489958
[No Abstract] [Full Text] [Related]
14. [Results of a phase-I clinical study of carboplatin--(cyclobutane-1,1-dicarboxylate)diamineplatinum (II)].
Gorbunova VA
Vestn Akad Med Nauk SSSR; 1986; (5):45-7. PubMed ID: 3524054
[No Abstract] [Full Text] [Related]
15. Oxaliplatin: new opportunities for the treatment of gastrointestinal cancer.
MacDonald JS
Cancer Invest; 2002; 20(2):287-9. PubMed ID: 11901548
[No Abstract] [Full Text] [Related]
16. Platinum-based chemotherapy for inoperable non-small cell lung cancer: a real therapeutic progress?
Buccheri G
Lung Cancer; 1994 Jul; 11(1-2):115-7. PubMed ID: 7521731
[No Abstract] [Full Text] [Related]
17. Oxaliplatin in colorectal cancer: an overview.
Armand JP; Boige V; Raymond E; Fizazi K; Faivre S; Ducreux M
Semin Oncol; 2000 Oct; 27(5 Suppl 10):96-104. PubMed ID: 11049040
[No Abstract] [Full Text] [Related]
18. Carboplatin (JM-8, CBDCA). A new platinum compound.
Semin Oncol; 1989 Apr; 16(2 Suppl 5):1-48. PubMed ID: 2655092
[No Abstract] [Full Text] [Related]
19. [Platinum complexes as potential antineoplastic drugs].
Kuduk-Jaworska J
Postepy Hig Med Dosw; 1984; 38(3):281-322. PubMed ID: 6398870
[No Abstract] [Full Text] [Related]
20. Carboplatin: the clinical evaluation strategy.
Rozencweig M; Canetta R; Carter SK
Cancer Treat Rev; 1985 Sep; 12 Suppl A():137-44. PubMed ID: 3910217
[No Abstract] [Full Text] [Related]
[Next] [New Search]
